Joshua Krasnow, MD
Interventional Cardiology · Exeter, NHNPI 1114986205
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 335 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Abbott at 37.2% of the total. Reporting peaked in 2023 at $1,588 and has fallen 83.5% since, to $262 in 2025.
Across 335 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Pfizer$496
- Johnson & Johnson$470
- AstraZeneca$411
- Novartis$347
- Amgen$326
- plus $2K from 22 others
Across 65 payments — averaging $13,803 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$766K
- Abbott$131K
What the payments were for
- Food & beverage$6,222100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 121 | $2,318 |
| Pfizer | 22 | $496 |
| Johnson & Johnson | 31 | $470 |
| AstraZeneca | 28 | $411 |
| Novartis | 16 | $347 |
| Amgen | 20 | $326 |
| E.r. Squibb & Sons, L.L.C. | 16 | $284 |
| Gilead | 15 | $182 |
| Stryker | 1 | $176 |
| Novo Nordisk | 8 | $132 |
| Boston Scientific | 5 | $116 |
| Medtronic | 2 | $115 |
| Otsuka America Pharmaceutical, Inc. | 5 | $111 |
| Boehringer Ingelheim | 6 | $104 |
| Cardiovascular Systems Inc. | 9 | $103 |
| Merck | 5 | $93 |
| Regeneron Healthcare Solutions, Inc. | 6 | $85 |
| Sanofi-aventis U.S. LLC | 4 | $68 |
| Penumbra, Inc. | 2 | $64 |
| CMP Pharma, Inc. | 2 | $50 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Bayer | 2 | $33 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $29 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Philips North America LLC | 1 | $15 |
| Chiesi USA, Inc. | 1 | $12 |
| Abiomed | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,236 in reported general payments places this provider in the 55th percentile of 26 interventional cardiology providers in New Hampshire.
See all interventional cardiology providers in New Hampshire →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 212 | $219,007 |
| FarxigaDapagliflozin Propanediol | 39 | $41,835 |
| XareltoRivaroxaban | 24 | $32,454 |
| Repatha SureclickEvolocumab | 41 | $31,700 |
| JardianceEmpagliflozin | 18 | $21,642 |
| EntrestoSacubitril/Valsartan | 16 | $15,784 |
| BrilintaTicagrelor | 21 | $14,494 |
| Repatha PushtronexEvolocumab | 11 | $8,788 |
| Ezetimibe | 128 | $4,670 |
| Ranolazine ErRanolazine | 23 | $2,758 |
| Metoprolol Succinate | 191 | $2,682 |
| Rosuvastatin Calcium | 147 | $2,486 |
| Atorvastatin Calcium | 213 | $1,939 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 43 | $1,688 |
| ClopidogrelClopidogrel Bisulfate | 84 | $1,089 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $496 | $219,007212 claims |
| AstraZenecaFarxiga, Brilinta | $411 | $56,32960 claims |
| Johnson & JohnsonXarelto | $470 | $32,45424 claims |
| Boehringer IngelheimJardiance | $104 | $21,64218 claims |
| NovartisEntresto | $347 | $15,78416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 26 interventional cardiology providers in New Hampshire.
Other interventional cardiology in Exeter
- Lazaro DiazExeter$15K
- Jessica SutherlandExeter$2K
- Shahab MoossaviConcord$36K
- Nitish SharmaDover$23K
- Rodrigo Mendirichaga MaganaDover$21K
- Hannah ChaudryLebanon$20K
- Eric RothsteinLebanon$20K
- James DevriesLebanon$19K
- Xiaoyu Yang-GiulianoManchester$18K
- Aaron KaplanLebanon$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.